Multiple sclerosis: New measures to monitor the disease

The Lancet Neurology

Volumn 12, Issue 1, 2013, Pages 12-13

  Filippi, Massimo ^a   Rocca, Maria A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FINGOLIMOD; FIRATEGRAST; FUMARIC ACID DIMETHYL ESTER; LAQUINIMOD; NATALIZUMAB;

DEMYELINATING DISEASE; DEMYELINATION; DRUG SAFETY; EARLY DIAGNOSIS; ENCEPHALOMYELITIS; HUMAN; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; SENSITIVITY AND SPECIFICITY;

BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84870808524     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70288-0     Document Type: Note

References (13)

1. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
2. Sadaka Y, Verhey LH, Shroff MM, et al. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol 2012, 72:211-223.
3. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
4. Filippi M, Rocca MA, Calabrese M, et al. Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology 2010, 75:1988-1994.
5. Giorgio A, Stromillo ML, Rossi F, et al. Cortical lesions in radiologically isolated syndrome. Neurology 2011, 77:1896-1899.
6. Sinnecker T, Dorr J, Pfueller CF, et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology 2012, 79:708-714.
7. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012, 367:1098-1107.
8. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012, 366:1000-1009.
9. Miller DH, Weber T, Grove R, et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2012, 11:131-139.
10. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1829-1839.
11. Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012, 135:2925-2937.
12. Chang A, Staugaitis SM, Dutta R, et al. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol 2012, published online Oct 17. 10.1002/ana.23693.
13. Kolasinski J, Stagg CJ, Chance SA, et al. A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain 2012, 135:2938-2951.